Comparison · NCT00744965-eb8bea59
Glyburide vs Placebo: Chorioamnionitis
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Glyburide vs Placebo: Chorioamnionitis. Trial comparisons, record NCT00744965-eb8bea59. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00744965-eb8bea59
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0794 | 0.0487 | 0.127 | wilson | |
| Risk in group 2 | 0.0645 | 0.0373 | 0.109 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0148 | -0.0395 | 0.0695 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.23 | 0.592 | 2.56 | log | |
| Odds ratio, group 1 over group 2 | 1.25 | 0.569 | 2.75 | log | |
| Number needed to treat, for one more participant with the outcome on Glyburide than on Placebo | 67.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Glyburide | Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.~Glyburide: Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control. | 15 | 189 | OG001 |
| Group 2 | Placebo | Women with mild gestational diabetes will be started ADA diet and placebo.~Placebo: Sham dose adjustments of the placebo will be made. | 12 | 186 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Chorioamnionitis
- Description
- Maternal fever \>=38.0°C
- Time frame
- intrapartum
- Population
Source ClinicalTrials.gov
Trial
- Title
- Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo
- NCT number
- NCT00744965
- Phases
- PHASE4
- Conditions
- Mild Gestational Diabetes
- Interventions
- Glyburide, Placebo
- Lead sponsor
- University of Texas Southwestern Medical Center
- Results first posted
- 2020-03-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00744965?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00744965-eb8bea59